Source:http://linkedlifedata.com/resource/pubmed/id/14620859
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2003-11-17
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1424-6074
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
113
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
105-7; discussion 115-6
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading | |
pubmed:year |
2003
|
pubmed:articleTitle |
Re-processing of biological products: regulatory considerations from the CBER perspective.
|
pubmed:affiliation |
Division of Therapeutic Proteins, CBER, FDA, Rockville, Maryland 20852, USA. shacter@cber.fda.gov
|
pubmed:publicationType |
Journal Article
|